六月 2026
- Home
- CollPlant
六月 2026的CollPlant市场份额分析
Innovating the Future of Regenerative Medicine We are a regenerative medicine company developing innovative technologies and products for medical aesthetics, tissue regeneration, and organ manufacturing. Learn more We use cookies to show you content that is relevant to you. By clicking “Accept”, you agree to the storing of cookies on your device to enhance site […]
CollPlant(包含公司地区分支机构)
查看更多网站流量和参与度信息- collplant.com
CollPlant收入截至 六月 2026为 15M - 25M
CollPlant主要域名产生的收入
3 年中CollPlant主要域名的收入
CollPlant主要域名的收入
CollPlant热门域名的总访问量
了解CollPlant市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
CollPlant热门域名的平均访问时长
分析CollPlant参与度指标。
过去 3 个月的平均访问时长
子公司明细
CollPlant热门域名的平均页面浏览量
了解CollPlant如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
CollPlant 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻CollPlant Holdings is developing regenerative breast implants using the Origin platform.The intersection of additive manufacturing and breast reconstruction has drawn notable players: CollPlant Biotechnologies partnered with Stratasys to develop and test regenerative breast implants using the Origin(R) platform, while BellaSeno reported one-year clinical results for its own resorbable 3D-printed scaffolds.
五月 21, 2026阅读更多
新闻CollPlant Holdings launched redesigned corporate website at collplant.com on Mar 18th '26.REHOVOT, Israel, March 18, 2026 /PRNewswire/ - CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human collagen (rhCollagen), today announced the launch of its redesigned corporate website at www.collplant.com.
三月 18, 2026阅读更多
新闻CollPlant Holdings launches Korean Patent allowance Secured.CollPlant Biotechnologies announces Korean Patent allowance Secured for its photocurable dermal filler.
二月 26, 2026阅读更多
查看 CollPlant 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。
